Who Paid My Doc
Oxlumo
Drug Genetic Disease
NDC 71336-1002-1
General payments
$815,671
Research payments
$3,096,084
Through program year 2025, $815,671 in general payments and $3,096,084 in research payments were reported against Oxlumo (Genetic Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
12 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $35,384 | 398 |
| 2025 | Research | $69,845 | 3 |
| 2024 | General | $51,112 | 538 |
| 2024 | Research | $227,596 | 30 |
| 2023 | General | $120,126 | 1,038 |
| 2023 | Research | $599,603 | 230 |
| 2022 | General | $114,080 | 759 |
| 2022 | Research | $1,125,863 | 249 |
| 2021 | General | $277,507 | 1,239 |
| 2021 | Research | $348,773 | 72 |
| 2020 | General | $217,462 | 124 |
| 2020 | Research | $724,404 | 94 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 30 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 30 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
4,096 general · 678 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.